A new approach to the development of a vaccine against meningococci of serogroups A and B was proposed. It involves the synthesis of conjugates of high-molecular capsule polysaccharides of the serogroup A meningococcus (PsA) with earlier synthesized protective fragments of membrane proteins from serogroup B meningococci. The conjugates were synthesized using a method that consists of the generation of aldehyde groups by oxidizing free vicinal hydroxyl groups of PsA and subsequent reaction of these groups with amino groups of the peptide. The reaction proceeds with the intermediate formation of the Schiff base, which is reduced to the stable secondary amine. The main parameters of the reaction were optimized in the synthesis of a PsA conjugate with a model peptide and methods of their characterization were developed. The reproducibility and efficiency of the synthetic procedure were demonstrated by the example of synthesis of PsA conjugates with fragments of protein PorA from the outer membrane of the serogroup B meningococcus. It was shown that, when administered without adjuvant, a conjugate of PsA with a protective peptide, which represents an exposed conserved fragment 306-332 of protein PorA, stimulates the formation of antibodies to the peptide and polysaccharide moieties of the molecule and is also capable of decreasing the degree of bacteremia in animals infected with serogroup A and serogroup B meningococci. The approach can be applied to the development of a complex vaccine for serogroup A and serogroup B meningococci.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1134/s1068162008050051 | DOI Listing |
Clin Exp Pediatr
January 2025
Department of Pediatrics, Hallym University Sacred Heart Hospital, Anyang, Korea.
Background: Patients with systemic lupus erythematosus (SLE) are susceptible to infectious diseases owing to various immunosuppressive treatments and disease characteristics. Meningococcal infections progress rapidly with a high incidence of severe complications and mortality; therefore, meningococcal vaccination is needed. However, there is limited evidence regarding the immunity and immunogenicity of patients with SLE.
View Article and Find Full Text PDFVaccines (Basel)
November 2024
Laboratory of Proteolytic Enzyme Chemistry, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia.
IgA1 protease is one of the virulence factors of , and other pathogens causing bacterial meningitis. The aim of this research is to create recombinant proteins based on fragments of the mature IgA1 protease A-P from serogroup B strain H44/76. These proteins are potential components of an antimeningococcal vaccine for protection against infections caused by pathogenic strains of and other bacteria producing serine-type IgA1 proteases.
View Article and Find Full Text PDFMicroorganisms
December 2024
Institut Pasteur, Invasive Bacterial Infections, Université Paris Cité, 75015 Paris, France.
Most cases of invasive meningococcal disease (IMD) in Europe are caused by isolates of the serogroups B, C, W, and Y. We aimed to explore cases caused by other unusual serogroups. We retrospectively screened IMD cases in the databases of the National Reference Center for Meningococci and in France between 2014 and 2023.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2024
Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Manchester, UK.
IJID Reg
December 2024
Institut Pasteur d'Algérie, Chéraga, Algeria.
Objectives: To monitor the spread of invasive meningococcal disease due to group C of the clonal complex 10217 isolates beyond the sub-Saharan African meningitis belt.
Methods: Cases were confirmed by real-time polymerase chain reaction in blood or cerebrospinal fluid samples and further characterized by multi-locus sequence typing that defined sequence type and clonal complexes. Sequencing of gene (encoding the penicillin-binding protein 2) was also used to predict susceptibility to β-lactams.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!